leadf
logo-loader
viewZIOPHARM Oncology Inc.

ZIOPHARM Oncology shares up on joint venture in China and Korea

Eden BioCell will be owned 50-50 by Ziopharm and TriArm

Cancer cells
ZIOPHARM Oncology is a biotechnology company that focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens

Ziopharm Oncology Inc (NASDAQ:ZIOP) shares moved higher Wednesday after announcing it will partner with TriArm Therapeutics Ltd in a venture called Eden BioCell Ltd to lead clinical development and commercialization of Sleeping Beauty-generated CAR-T therapies in China, Korea and the territories of Macau and Hong Kong. 

Ziopharm will license the rights to Eden BioCell for third-generation Sleeping Beauty-generated CAR-T therapies targeting the CD19 antigen.

READ: Ziopharm Oncology shares tumble after FDA places clinical hold on cancer trial

Eden BioCell will be owned 50-50 by Ziopharm and TriArm. TriArm has committed up to $35 million to this joint venture.

Under the terms of the agreement, Eden BioCell has rights in the region to CAR-T cells that are rapidly manufactured in two days or less using the Sleeping Beauty platform to express a CD19-specific CAR and membrane-bound interleukin-15, or mbIL15, along with a kill switch.

“Advancing our Sleeping Beauty platform in the China region is a key part of both our business development and clinical development strategies,” said Ziopharm CEO Laurence Cooper.

Shares of Ziopharm rose over 9% to $21.76 in early trade.

TriArm is a cell therapy company with operations in Germany, China and the United States that was formed by Panacea Venture Healthcare, a fund co-founded and managed by James Huang, the Managing Partner of Kleiner Perkins Caufield & Byers China (KPCB China).

TriArm will manage all clinical development to execute trials in China for Eden BioCell. The TriArm team has considerable experience in all areas of drug development, including scientific research, clinical and regulatory areas, as well as significant laboratory and manufacturing know-how regarding T-cell therapies.

Ziopharm Oncology is a biotechnology company that focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.

The company is based in Boston.

Contact Rene Pastor by [email protected]

Quick facts: ZIOPHARM Oncology Inc.

Price: 2.83 USD

NASDAQ:ZIOP
Market: NASDAQ
Market Cap: $606.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Ascendant Resources drill program continues looking to expand south zone at...

Ascendant Resources (TSE: AND) President and CEO Chris Buncic joined Steve Darling from Proactive with news the company's drill program continues as the look at the South Zone of the Lagoa Salgada Project in Portugal. Buncic telling Proactive they are expecting to have results from this...

6 hours, 33 minutes ago

2 min read